176 related articles for article (PubMed ID: 11866974)
1. [Relationship between genetic alterations and clinicopathological features in intrahepatic cholangiocarcinoma].
Cong W; Finkelstein SD; Wu M
Zhonghua Bing Li Xue Za Zhi; 2001 Jun; 30(3):183-7. PubMed ID: 11866974
[TBL] [Abstract][Full Text] [Related]
2. Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study.
Cong WM; Bakker A; Swalsky PA; Raja S; Woods J; Thomas S; Demetris AJ; Finkelstein SD
J Cancer Res Clin Oncol; 2001; 127(3):187-92. PubMed ID: 11260864
[TBL] [Abstract][Full Text] [Related]
3. [Genotyping of multiple genetic alterations of intrahepatic cholangiocarcinoma].
Cong W; Wu M; Chen H
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):271-3. PubMed ID: 11798885
[TBL] [Abstract][Full Text] [Related]
4. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.
Kang YK; Kim WH; Lee HW; Lee HK; Kim YI
Lab Invest; 1999 Apr; 79(4):477-83. PubMed ID: 10212000
[TBL] [Abstract][Full Text] [Related]
5. [Study on loss of heterozygosity and microsatellite instability in hepatocellular carcinoma].
Cong WM; Zhang SH; Xian ZH; Wu WQ; Wu MC
Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):71-4. PubMed ID: 15842799
[TBL] [Abstract][Full Text] [Related]
6. Allelic loss in human intrahepatic cholangiocarcinoma: correlation between chromosome 8p22 and tumor progression.
Kawaki J; Miyazaki M; Ito H; Nakagawa K; Shimizu H; Yoshidome H; Uzawa K; Tanzawa H; Nakajima N
Int J Cancer; 2000 Oct; 88(2):228-31. PubMed ID: 11004673
[TBL] [Abstract][Full Text] [Related]
7. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients.
Petmitr S; Pinlaor S; Thousungnoen A; Karalak A; Migasena P
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):71-5. PubMed ID: 9740272
[TBL] [Abstract][Full Text] [Related]
8. [Frequency of loss of heterozygosity on chromosome 17 in intrahepatic cholangiocarcinoma].
Kim HJ; Kang CD; Lee SJ; Cho SJ; Kim JS
Korean J Gastroenterol; 2006 Sep; 48(3):188-94. PubMed ID: 17047434
[TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma.
Tannapfel A; Sommerer F; Benicke M; Weinans L; Katalinic A; Geissler F; Uhlmann D; Hauss J; Wittekind C
J Pathol; 2002 Aug; 197(5):624-31. PubMed ID: 12210082
[TBL] [Abstract][Full Text] [Related]
10. [A study on the loss of heterozygosity at the APC/MCC and DCC genetic loci in colorectal cancers].
Lui Y; Fang D; Lu R
Zhonghua Nei Ke Za Zhi; 1996 Jul; 35(7):439-43. PubMed ID: 9592312
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy.
Chen TC; Jan YY; Yeh TS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S675-81. PubMed ID: 22805857
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
14. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
[TBL] [Abstract][Full Text] [Related]
15. Allelotype analysis of intrahepatic cholangiocarcinoma.
Kang YK; Kim YI; Kim WH
Mod Pathol; 2000 Jun; 13(6):627-31. PubMed ID: 10874666
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma.
Momoi H; Okabe H; Kamikawa T; Satoh S; Ikai I; Yamamoto M; Nakagawara A; Shimahara Y; Yamaoka Y; Fukumoto M
Clin Cancer Res; 2001 Sep; 7(9):2648-55. PubMed ID: 11555575
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features.
Horie S; Endo K; Kawasaki H; Terada T
Virchows Arch; 2000 Jul; 437(1):25-30. PubMed ID: 10963376
[TBL] [Abstract][Full Text] [Related]
18. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract.
Abraham SC; Lee JH; Hruban RH; Argani P; Furth EE; Wu TT
Hum Pathol; 2003 Sep; 34(9):902-10. PubMed ID: 14562286
[TBL] [Abstract][Full Text] [Related]
20. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
